Y Intercept Hong Kong Ltd Takes $9.88 Million Position in Cencora, Inc. $COR

Y Intercept Hong Kong Ltd purchased a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 29,249 shares of the company’s stock, valued at approximately $9,879,000.

A number of other hedge funds have also made changes to their positions in COR. Norges Bank purchased a new position in shares of Cencora in the fourth quarter valued at $822,506,000. Marshall Wace LLP increased its position in shares of Cencora by 518.9% in the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after buying an additional 1,672,762 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock valued at $461,250,000 after buying an additional 1,241,186 shares in the last quarter. Viking Global Investors LP boosted its stake in shares of Cencora by 95.0% during the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Cencora by 4.1% during the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after acquiring an additional 916,506 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.0%

COR opened at $281.56 on Friday. The business’s fifty day simple moving average is $289.22 and its 200 day simple moving average is $327.63. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The firm has a market cap of $54.78 billion, a P/E ratio of 21.59, a PEG ratio of 1.52 and a beta of 0.59.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm earned $4.42 EPS. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s payout ratio is 18.40%.

Cencora announced that its board has approved a stock repurchase plan on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 3.9% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of analysts recently commented on COR shares. Evercore set a $360.00 price objective on Cencora in a research note on Wednesday, April 8th. Weiss Ratings lowered Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 22nd. Wells Fargo & Company decreased their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Robert W. Baird decreased their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Twelve analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.